Interventional Validation of an MDS-Specific Measure of Quality of Life: Assessing the Responsiveness of the Quality of Life in Myelodysplasia Scale (QUALMS-1) to Different Hypomethylating Agent Regimens for Low and Intermediate Risk Disease
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 240
Summary
- Conditions
- Leukemia
- Type
- Observational
- Design
- Observational Model: CohortTime Perspective: Prospective
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
If you agree to take part in this study, you will be asked to complete questionnaires twice during your participation in the 2014-0112 study. During your first treatment visit, you will be asked to complete the QUALMS-1 questionnaire and another questionnaire that asks about your well-being. After y...
If you agree to take part in this study, you will be asked to complete questionnaires twice during your participation in the 2014-0112 study. During your first treatment visit, you will be asked to complete the QUALMS-1 questionnaire and another questionnaire that asks about your well-being. After your 4th cycle of treatment or when you stop receiving treatment, you will be asked to complete the QUALMS-1 questionnaire again and another questionnaire to rate any changes in your health since you started the study. It should take about 20 minutes total to complete the questionnaires each time. Information will also be collected from your medical record. This information will include the results of lab tests and other information relating to your health. Length of Study Participation: After you complete the questionnaires the second time, your participation in this study will be complete.
Tracking Information
- NCT #
- NCT02378701
- Collaborators
- MDS Clinical Research Consortium
- Investigators
- Principal Investigator: Guillermo Garcia-Manero, MD M.D. Anderson Cancer Center